Cancer is a complex disease. To find effective therapy for an individual patient, it is important to understand the underlying biology that drives a patient's tumor cells. New targeted agents have exhibited optimal effectiveness when a patient's specific tumor cell biology can be matched with a specific targeted therapy. Without understanding the biological protein expression and activated protein targets in a patient's tumor, it is more difficult to choose an effective targeted therapy for that patient.

Our team works to discover novel therapeutics designed to block activated protein pathways that drive cell proliferation and tumor development. Our goal is to develop targeted therapies that are very effective when matched with patients who have the specific target protein for the drug.

Our experienced researchers use cutting-edge techniques in computer-aided drug design to identify lead compounds and proof-of-mechanism studies to rapidly advance compounds from discovery to clinical candidates. Our team also has years of experience with approved anticancer agents. Understanding the efficacy and toxicity profiles for approved chemotherapeutics allows detailed evaluation of novel agents used in combination with standard courses of cancer therapy.

Our laboratory and clinical teams have been involved in developing some of the most important cancer drugs used today.